McDermott Will & Schulte

On September 25, at the Peninsula, London, we’re bringing together the people driving the most interesting deals, boldest bets, and smartest growth strategies in health and life sciences. You’ll hear from: ✔️ Founders behind Europe’s fastest-growing platforms. ✔️ Investors deploying serious capital across medtech, pharma and AI. ✔️ Strategics reshaping care delivery and unlocking value. If you work in this space, you’ll want to be in the room. https://lnkd.in/ezsZUDka

Firm Chairman Ira Coleman and London Co-Managing Partner Aymen Mahmoud discussed with IFLR how our recent merger is strengthening the firm’s M&A platform and already delivering results with a team of more than 100 dedicated M&A lawyers. Ira called the merger a union of strengths: “McDermott has long been a leader in healthcare, tax, family office, PE and M&A, while Schulte brings deep expertise in private capital, investment management and financial services regulation.” That alignment is fueling rapid growth. “Between the merger and this additional talent, we’ve built out a full suite of capabilities at the intersection of PE, hedge funds, insurance, and financial services. This strategic expansion complements our existing investment management strengths and opens new doors for cross-industry growth.” Aymen underscored the global reach: “This merger doubles down on our commitment to being a leading player in [the London] market. Clients want seamless service across borders and across disciplines, and that’s exactly what we can deliver. London is a global gateway, and we’re using it to power high-impact solutions across the UK, Europe, and the US.” Looking ahead, Ira added: “Building a firm for the future means delivering for our clients and our people today while also anticipating what tomorrow will demand… Ultimately, success is about impact for our clients, our people and our role in shaping the future of the legal industry.”

Innovation is transforming the alcohol industry, bringing both new opportunities and a host of compliance challenges. From new product categories to shifting state-level regulations, staying compliant is more complex than ever. Join Alva Mather and Christine Dower as they answer your pressing questions and offer insights into navigating these changes effectively. Secure your spot today: https://lnkd.in/e3z_e_BR

📈 Aymen Mahmoud is the London managing partner of McDermott Will & Schulte - the US firm that recently completed one of the biggest law firm tie-ups in recent years, a $2.8bn merger with Schulte Roth & Zabel. Aymen got the top job in London last year at the age of just 39, making him one of the youngest leaders in Big Law. In a conversation for The Non-Billable Podcast, he tells us how the merger came together and what the combined platform means for clients on both sides of the Atlantic. We also dig into the London story: how Schulte’s top-tier funds practice changes McDermott’s position in the market, the firm’s plans for a new Mayfair office in 2028, and the ambition to be on every top client’s speed dial for private capital work. Episode links in the comments.

🔦 Session Spotlight: AI, Alt Data, and Compliance — From Governance to Exams 🔦   As AI shifts from pilots to production, funds face a new compliance frontier. Governance, model vetting, vendor diligence, contractual protections, and regulatory expectations are no longer optional—they’re core. Our session with McDermott Will & Schulte brings practical guidance on what 'good' looks like: building policies that regulators respect, onboarding models and data with rigor, controlling accuracy, staying exam-ready, and navigating how AI is reshaping alternative data oversight.   Join Tinika Brown Davis & Malik Rollins from McDermott Will & Schulte and our own Ciaran Ryan, for concrete takeaways on building defensible AI programs, negotiating enterprise AI agreements, adapting compliance frameworks for AI-mediated datasets, and tracking key rulemakings (Form PF, Reg SP, SEC/CFTC agenda).   📍 New York City | 🗓️ September 17 🔗 Register: https://lnkd.in/ezD2g_BA

🚨 Last week, FTC Chairman Andrew N. Ferguson warned large healthcare employers and staffing firms that overly broad noncompete agreements could face enforcement. The FTC is signaling a shift toward case-by-case action, putting healthcare employers on notice. Read more here: https://bit.ly/4gkUYdb Authors: Barrick Bollman | Pankit Doshi | Max Garfield | Ron Richman | Martin Schmelkin | Stephen Wu | Nicholas Neathamer

🔓Agenda unlocked! Programming details for the Life Sciences Investment Forum are now live. From the latest on liquidity and AI's impact to evolving strategies for private equity and growth capital, we’re focused on the conversations that matter. Expect sharp insights, actionable takeaways, and unmatched networking with senior investors and executives. 📍 The Newbury Boston 📅 November 13, 2025 🎟️ Seats are limited – secure your spot now https://lnkd.in/eBd_QzzF

The US privacy landscape didn’t stand still in 2025 — even without new comprehensive laws. Instead, meaningful shifts emerged as states amended existing privacy frameworks, biometric data collection faced increased scrutiny, and protections for minors online were expanded. Join David Saunders and Andrew Chappell, senior privacy counsel at Lyft, for a practical discussion on what these changes mean for your organization and how to prepare for what’s next. Register today: https://lnkd.in/eWeyU7tA

Antitrust enforcement is entering new territory. Companies need to be prepared. In our next Global Antitrust Update webinar, we’ll unpack rising scrutiny around labor markets, minority shareholdings and interlocking directorates. From the European Delivery Hero decision to growing US enforcement, these trends are reshaping global compliance expectations. We’ll also highlight the latest enforcement headlines and offer practical guidance to help you stay ahead. Register here: https://lnkd.in/dvdM4fj8

On 4 September, the European Court of Justice handed down a landmark ruling confirming that pseudonymised data may, in certain cases, be considered anonymised in the hands of a third party. This pragmatic “whose hands” test will be welcomed by organisations that share and re-use data, particularly across the life sciences sector. It also raises important questions on re-identification risk and the scope of transparency obligations for data controllers. Our European colleagues Sharon Lamb and Lorraine Maisnier - Boché analyse what this means for businesses handling personal data. With deep expertise in data protection, privacy compliance and life sciences regulation, they help clients design robust anonymisation and pseudonymisation strategies, adapt privacy risk assessments and develop governance frameworks that meet evolving regulatory standards. 📘 Read their full analysis: https://lnkd.in/gf3Gd_Jb